Status:
UNKNOWN
Immunity After COVID-19 Vaccination
Lead Sponsor:
Plexision
Conditions:
Immunity to COVID-19
Eligibility:
All Genders
18-100 years
Brief Summary
The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after...
Detailed Description
Study type: Open-label, prospective, non-randomized, observational study. Risk level. Minimal risk. Blood sampling: 10 ml each time, up to 8 times in 12 month study period for each subject, minimum ...
Eligibility Criteria
Inclusion
- IRB-approved informed consent,
- age 18 years or older, male or female,
- anyone considering COVID-19 vaccination or anyone that has received COVID-19 vaccination.
- Subjects can enroll at anytime after vaccination even though they may not have enrolled before vaccination.
- For individuals previously tested at Plexision for other purposes, and who have since been vaccinated, residual cells stored for quality control and potential repeat testing will be used to establish earlier measurement of cellular and antibody immunity as described in Table 1.
Exclusion
- Failure to provide informed consent
Key Trial Info
Start Date :
April 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04883164
Start Date
April 27 2021
End Date
March 31 2023
Last Update
May 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Plexision
Pittsburgh, Pennsylvania, United States, 15224